The growth inhibitiory effect of new pyrrolo[1,2-alpha]benzimidazole derivatives on human gastric cancer cells

Arch Pharm Res. 1997 Oct;20(5):410-3. doi: 10.1007/BF02973931.

Abstract

In the course of screening synthetic compounds to inhibit tumor cell growth, pyrrolo[1,2-alpha] benzimidazole (PBI), an intermediate of azamitosene, was found to inhibit a proliferation of gastric cancer cell lines. Despite a potential cytotoxic activity against solid tumor cells as opposed to that against rapidly-doubled leukemic cells, there has been no report on the inhibition of gastric cancer cell line by PBI and its' derivatives. The present experiment was designed to determine if PBI derivatives can effectively inhibit the cellular proliferation of gastric cancer cells by usingin vitro as well asin vivo chemosensitivity system (MTT assay, clonogenic assay and human tumor xenografted assay). Of the tested PBI derivatives, PBI (18) and PBI (20), displayed the effective growth inhibition of cultured gastric cancer cells or even in the xenografted nude mouse model.